Three biotechs raise $100M+ in fund­ing for gene ther­a­pies, can­cer vac­cines and more

→ An­oth­er day, an­oth­er gene ther­a­py de­vel­op­er. Pre­vail Ther­a­peu­tics, which leapt out of stealth mode in 2017 and raised $75 mil­lion in a Se­ries A last year for its dis­ease-mod­i­fy­ing ap­proach to neu­rode­gen­er­a­tive dis­eases, has se­cured an­oth­er $5o mil­lion in the bank. The New York-based com­pa­ny is run by Co­lum­bia Uni­ver­si­ty’s Asa Abe­liovich, who helped co-found Alec­tor, which is go­ing af­ter Alzheimer’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER